Premium
Hypersensitivity to inhaled TOBI ® following reaction to gentamicin
Author(s) -
Spigarelli Michael G.,
Hurwitz Martin E.,
Nasr Samya Z.
Publication year - 2002
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.10049
Subject(s) - medicine , rash , discontinuation , inhalation , tobramycin , cystic fibrosis , gentamicin , desensitization (medicine) , hypersensitivity reaction , pseudomonas aeruginosa , antibiotics , anesthesia , dermatology , immunology , microbiology and biotechnology , genetics , receptor , bacteria , biology
Cystic fibrosis (CF) is the most common autosomal‐recessive disease in Caucasians. Colonization with Pseudomonas aeruginosa ( P. aeruginosa ) of the CF airways causes deterioration of pulmonary status. TOBI ® (Tobramycin solution for inhalation) is an inhaled antibiotic that can improve the pulmonary disease. We report on a 9‐year old boy with CF who developed a rash following a course of IV gentamicin. The rash resolved after its discontinuation. However, the rash returned all over his body, with the start of inhalation of TOBI ® therapy. We desensitized the patient using escalating doses of inhaled TOBI ® . He tolerated the procedure well, and continues to be on TOBI ® 9 months after desensitization on a once‐a‐day regimen. Pediatr Pulmonol. 2002; 33:311‐314. © 2002 Wiley‐Liss, Inc.